Pharmaceutical Industry Archives - CINRX Pharma

HOME
ABOUT
NEWS
CONTACT US

HOME
ABOUT
NEWS
CONTACT US

Web tile – 500x200 – cinrxpharma

CinRx News
May 30, 2024

CinRx Pharma Announces Additional $73 Million Financing

CinRx Pharma Announces Additional $73 Million Financing

Search

About Author

At Labstica, we believe in the power of collaboration, innovation, and continuous growth – both for our clients and ourselves.

LinkedIn
Instagram
Twitter
Facebook

Recent Post

CinDome Pharma Announces Completion of Enrollment in the envision^GI Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Idiopathic Gastroparesis

CinDome Pharma Announces Enrollment Completion in the envision^3D Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

September 9, 2025

CinDome Pharma Announces First Patient Dosed in Clinical Trial of Deudomperidone (CIN-102)

Tags

2023 Digestive Disease Week Conference Acquisition AstraZeneca Biotechnology Business Finance CIN-102 CIN-102 (deudomperidone) CinCor Pharma CinDome CinDome Pharma CinRx Pharma Deudomperidone Deuterated Domperidone Diabetic Gastroparesis envision Financing First Patient Dosed Funding Announcement Gastroparesis Healthcare Finance News Investment Pharmaceutical Funding Pharmaceutical Industry Phase 2 Clinical Trial Phase 2 Trial Poster presented Present a Poster Series B Extension vTv Therapeutics Inc.

844-531-1834 | info@cinrx.com

© 2025 CINRx Pharma. All Rights Reserved.

Site Pages

HOME
ABOUT
NEWS
CONTACT US

HOME
ABOUT
NEWS
CONTACT US

CINRx in The News

CinDome Pharma Announces Completion of Enrollment in the envision^GI Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Idiopathic Gastroparesis

March 17, 2026

CinDome Pharma Announces Enrollment Completion in the envision^3D Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

September 3, 2025

FOLLOW US

INVESTOR INQUIRIES

CinRx INQUIRIES

Inquiring About (Choose one)